New trends in the management of diabetic retinopathy

Advanced Studies in Medicine

Volumn 4, Issue 10 G, 2004, Pages

  Dodson, Paul M ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANTILIPEMIC AGENT; APTAMER; FIBRIC ACID DERIVATIVE; GROWTH HORMONE; GROWTH HORMONE ANTAGONIST; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; SOMATOMEDIN C; STEROID; UNCLASSIFIED DRUG; VASCULOTROPIN;

BLINDNESS; CONFERENCE PAPER; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROLIFERATIVE RETINOPATHY; PROTEINURIA; RETINA BLOOD FLOW; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RISK FACTOR; RISK MANAGEMENT; SCREENING TEST; TREATMENT OUTCOME;

EID: 11244309741     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Donaldson M, Dodsan PM. Medical treatment of diabetic retinopathy. Eye. 2003;17:550-562.
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;33:1480-1487.
3. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
4. Aiello LP, Bursell S, Devries T. Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes [abstract]. Diabetes. 1999;48:A19.
5. Milton RC, Aiello LP, Davis MD, et al. Initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS). Diabetologia. 2003;46(suppl 2):A42.
6. Aiello LP, Davis MD, Milton RC, et al. Initial results of the protein kinase C β inhibitor diabetic macular edema study (PKC-DMES). Diabetologia. 2003;46(suppl 2):A42.
7. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular edema. Retina. 2002; 22:143-152.
8. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept. 1993;48:267-278.
9. Kirkegaard C, Norgaard K, Snorgaard O, et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenhagen). 1990;122:766-772.
10. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504-509.
11. Luettke BLG, Boehm BO, Lang GK. Influence of a somatostatin analogue on the course of persisting proliferative diabetic retinopathy after laser treatment [abstract]. Invest Ophthalmol Vis Sci. 1998;39:A3100.
12. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology. 2001;108:2266-2272.
13. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atarvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.